Is Orforglipron FDA-Approved? What the Foundayo Label Actually Says

Yes — orforglipron is FDA-approved. It’s sold under the brand name Foundayo, and its prescribing information is published as an FDA-approved label on DailyMed, the National Library of Medicine’s official repository for approved drug labeling. Here’s exactly what that approval covers, what it doesn’t, and how to read the label yourself.

Is orforglipron FDA-approved?

Is Foundayo FDA-approved? Yes — orforglipron, marketed as Foundayo, has an FDA-approved label. You can verify this directly: DailyMed only hosts labeling for drugs the FDA has approved, and the FOUNDAYO entry there is the official prescribing information — the same document your pharmacist and prescriber use. That label spells out the approved indication, dosing and titration schedule, administration instructions, and side effects.

This matters because “FDA-approved” is a specific, checkable claim, not marketing language. It means the drug went through the FDA’s review process for safety and effectiveness data, for a defined use in a defined population — which is different from a drug being merely available, or being promoted online, or being compounded.

What is orforglipron actually approved for?

Per the FOUNDAYO label, orforglipron is approved for chronic weight management, used together with a reduced-calorie diet and increased physical activity, in adults who have:

• Obesity, or
• Overweight, along with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol)

That’s the approved indication — it’s specifically a weight-management drug, not a blanket approval covering every GLP-1 use. If you’re wondering whether it’s the right fit for your specific health picture, that’s a conversation for your prescriber; see our guide on who should take orforglipron for more on how that decision gets made.

Is orforglipron approved for type 2 diabetes?

No — not per its current approved indication. This is a genuinely useful distinction when comparing orforglipron to other GLP-1 medications, because approved uses differ across the class even though the drugs are chemically related:

Medication	Active ingredient	FDA-approved indication (per label)
Foundayo	Orforglipron	Chronic weight management
Ozempic	Semaglutide (injection)	Type 2 diabetes (blood sugar control); also cardiovascular/kidney-related uses per MedlinePlus
Rybelsus	Semaglutide (oral)	Type 2 diabetes (blood sugar control)
Mounjaro / Zepbound	Tirzepatide	Type 2 diabetes (Mounjaro) / chronic weight management (Zepbound), per MedlinePlus

If you have type 2 diabetes and are curious how orforglipron relates to semaglutide or tirzepatide, our comparisons of orforglipron vs. Ozempic and orforglipron vs. tirzepatide go into the mechanism and administration differences in more depth.

What FDA approval actually means — and doesn’t mean

It’s worth being precise about what this status does and doesn’t tell you:

• It does mean the FDA reviewed safety and efficacy data for the approved indication (chronic weight management, in the populations studied) and determined the drug met its standards for approval.
• It does mean the label — dosing, administration, warnings, side effects — is an authoritative, FDA-vetted document, not a manufacturer’s marketing claim.
• It doesn’t mean the drug is risk-free or appropriate for everyone. Every FDA-approved drug still carries side effects and contraindications, which is why the label includes them.
• It doesn’t mean you can get it without a prescription. Foundayo is a prescription-only medication — approval doesn’t change that.
• It doesn’t mean every insurance plan covers it, or that it’s the right choice for your specific situation. Coverage and clinical fit are separate questions from approval status; see our guide on insurance coverage for orforglipron if cost is part of your decision.

How to check the label yourself

You don’t have to take anyone’s word for this, including this article’s. The FOUNDAYO label is public on DailyMed (linked in the sources below) and includes the full approved indication, dosing schedule, contraindications, and side-effect information in the FDA’s own language. If you’re comparing it against a specific claim you’ve seen — a dosing detail, a side effect, an administration rule — the label is the primary source to check, and your pharmacist can walk through it with you.

Bottom line

Orforglipron (Foundayo) is FDA-approved, with an approved indication for chronic weight management in adults with obesity, or overweight plus a weight-related condition, alongside diet and exercise. It is not currently approved for type 2 diabetes, which is a different indication held by other GLP-1 medications like Ozempic, Rybelsus, and Mounjaro. Approval confirms the FDA reviewed the drug for its approved use — it doesn’t substitute for a conversation with your prescriber about whether it’s right for you. For the full picture on dosing and what to expect, see our Foundayo (orforglipron) guide.